**Sun Pharma Secures Court Ruling for Leqselvi Launch in the US**
Sun Pharmaceutical Industries Ltd has received a significant legal victory that clears the path for the launch of its specialty drug, Leqselvi, in the United States. On April 9, the US Court of Appeals for the Federal Circuit vacated a preliminary injunction that had previously halted the drug’s introduction to the market. This ruling allows Sun Pharma to move forward with its plans to launch Leqselvi, which is designed to treat alopecia areata, a condition that leads to hair loss.
The company had initially gained approval from the US Food and Drug Administration (FDA) for Leqselvi in July 2024. However, shortly after this approval, Incyte Corporation, a US biopharmaceutical firm, filed a patent infringement lawsuit against Sun Pharma, claiming that Leqselvi violated its existing patents. In November 2024, a preliminary injunction was granted by the US District Court of New Jersey, preventing the launch of Leqselvi until the legal dispute was resolved.
With the recent court ruling lifting the injunction, Sun Pharma is now free to proceed with the launch of Leqselvi, although the broader patent litigation with Incyte remains ongoing. The company stated in a regulatory filing that it is no longer bound by any court orders that would delay the launch and will announce its plans for Leqselvi in due course.
The uncertainty surrounding the launch had previously impacted Sun Pharma’s stock prices, leading to a cautious outlook from brokerages. In earlier earnings calls, the company indicated that if the legal outcomes were unfavorable, it might have to wait until the patent expires in December 2026 to launch the drug. Dilip Shanghvi, the chairman and managing director of Sun Pharma, noted in a February investor call that the patent is valid until December 2026, and unfavorable judgments could delay the launch.
Market analysts, including those from Elara Capital, estimate that Leqselvi could represent a $200 million opportunity for Sun Pharma within three to four years post-launch.
**FAQ**
*What is Leqselvi used for?*
Leqselvi is a specialty drug developed by Sun Pharma to treat alopecia areata, a condition that causes hair loss or baldness.
